Merck & Co (MRK)

Even if the company's vaccine obtains approval, producing it at scale could be a big challenge.

In 2022, the last time rates rose quickly, these stocks surged, a couple of them by more than 80%.

Tempus AI posted Q3 revenue up 23.1% and a surprise profit, raised guidance, and saw shares surge 10%, though analysts cite cash burn and limited 2026 upside.

The market for GLP-1 drugs is forecast to explode. It may be understated still.

Investors were still buying it in the afterglow of its latest quarterly earnings release.

Global pharmaceutical company Merck (NYSE:MRK) reported revenue ahead of Wall Street’s expectations in Q3 2026, with sales up 4.7% year on year to $18.09 bil...

Merck & Co., Inc. (NYSE:MRK) reported third-quarter 2026 revenue of $18.1 billion, up 5% from a year earlier, as growth in oncology, vaccines, cardiometabolic products and animal health helped offset product-specific and market headwinds. Non-GAAP earnings per share were $2.49 for the quarter,

Generic headwinds ahead in 2027, but new launches and WINREVAIR growth signal momentum.

Merck’s new drugs are growing fast enough to cover generic losses, but part of this quarter’s sales gain won’t last. Here’s what to watch.

Global pharmaceutical company Merck (NYSE:MRK) announced better-than-expected revenue in Q3 2026, with revenue rising 4.7% year on year to $18.09 billion. Th...

The path for Revolution Medicines to grow an initial investment of $25,000 into $1 million is a daunting one.

Global pharmaceutical company Merck (NYSE:MRK) will be reporting earnings this Thursday before market open. Here’s what investors should know. Merck beat ana...

Merck and Moderna's melanoma vaccine cut recurrence risk 42% in a Phase 3 trial, but results fell short of hopes, sending Moderna shares down sharply while Merck stock barely moved.

Merck & Co., Inc. (NYSE:MRK) outlined new oncology data and development plans at the European Society for Medical Oncology annual meeting, highlighting phase III results for its sacituzumab tirumotecan, or sac-TMT, antibody-drug conjugate in endometrial cancer and its individualized neoantigen t

MercadoLibre, Novo Nordisk, Tyler Technologies and Summit Therapeutics trade below recent highs, yet each has earnings or catalysts that could shift sentiment.

Lincoln National, AbbVie and Phillips 66 offer dividends that pay investors through midterm volatility, backed by rising rates, steady drug demand and oil risk.

The market has rewarded this biotech for its breakthroughs.

This company made headlines with its coronavirus vaccine.